Skip to main content Skip to main navigation menu Skip to site footer
logo Mediterranean Journal of Hematology and Infectious Diseases

eISSN 2035-3006

  • Home
  • About the Journal
  • Editorial Board
  • Current
  • Archives
  • Announcements
  • Register
  • Login
  • Journal Statistics
  • Search
  • Contact
  • Announcements

Editor-in-Chief: Giuseppe Leone | Italy

2.3
Impact Factor 2025
3.2
CiteScore 2025
2.3
Impact Factor 2025
3.2
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

    Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli
    e2016011
    2016-02-10
    https://doi.org/10.4084/mjhid.2016.011
    4399
    PDF: 1517
    HTML: 3719
  • RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

    Antonio Cuneo, Robin Foà
    e2019024
    2019-02-27
    https://doi.org/10.4084/mjhid.2019.024
    2768
    PDF: 1690
    HTML: 386
  • NOVEL DRUGS IN FOLLICULAR LYMPHOMA

    Giuseppe Rossi, Antonella Anastasia
    e2016061
    2016-11-01
    https://doi.org/10.4084/mjhid.2016.061
    5063
    PDF: 1549
    HTML: 1655
    Untitled: 244
  • INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

    Livio Pagano, Davide Facchinelli, Dr.
    e2018063
    2018-10-27
    https://doi.org/10.4084/mjhid.2018.063
    2097
    PDF: 1137
    HTML: 338
  • THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

    Francesco Maura, Lucia Farina, Paolo Corradini
    e2016045
    2016-09-01
    https://doi.org/10.4084/mjhid.2016.045
    4130
    PDF: 1175
    HTML: 2101
    Fig.1: 224
    Fig. 2: 120
    Table 1: 212
    Table2: 232
    Table 3: 208
  • WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

    Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi
    e2018004
    2018-01-01
    https://doi.org/10.4084/mjhid.2018.004
    7752
    PDF: 2460
    HTML: 2101
    Table 1.: 233
    Table 2.: 242
    Table 3.: 225
    Table 4.: 218
  • GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

    Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis
    e2025014
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.014
    1462
    HTML: 164
    PDF: 895
  • FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

    Alessia Castellino, Umberto Vitolo
    e2017009
    2017-01-01
    https://doi.org/10.4084/mjhid.2017.009
    4497
    PDF: 1663
    HTML: 4214
    Tables and Images: 250
  • INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?

    Francesco Zallio, Giulia Limberti, Marco Ladetto
    e2017035
    2017-05-01
    https://doi.org/10.4084/mjhid.2017.035
    3295
    PDF: 1043
    HTML: 2225
  • MANAGING INVASIVE FUNGAL INFECTIONS DURING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A 2025 UPDATE

    Martina Quattrone, Alessia Di Pilla, Sara Brunetti, Antonio Giordano, Luana Fianchi, Livio Pagano, Marianna Criscuolo
    e2025064
    2025-08-31
    https://doi.org/10.4084/MJHID.2025.064
    2333
    PDF: 964
    HTML: 262
  • “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

    Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin
    e2016047
    2016-10-15
    https://doi.org/10.4084/mjhid.2016.047
    4044
    PDF: 1073
    HTML: 3889
    Untitled: 184
    Cneo. Fig.1: 120
    Untitled: 113
    Untitled: 140
    Untitled: 146
  • Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

    Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca
    e2025061
    2025-08-31
    https://doi.org/10.4084/MJHID.2025.061
    1301
    PDF: 588
    Html: 230
  • BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

    Stefano Molica
    e2025053
    2025-06-29
    https://doi.org/10.4084/MJHID.2025.053
    1696
    PDF: 978
    HTML: 307
  • WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

    Michele Bibas, Shayna Sarosiek , Jorge Castillo
    e2025015
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.015
    2655
    PDF: 2055
    HTML: 240
1 - 14 of 14 items
Make a Submission

Links

  • Editorial Board
  • Alert me!
  • Advertising
  • Scopus
  • DOAJ
  • Article Processing Charge

Information

  • For Readers
  • For Authors
  • For Librarians

Indexing

  • OpenAlex
  • Analytics

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

this journal is covered
by Clarivate Analytics

 

The Mediterranean Journal of Hematology and Infectious Diseases has been selected for coverage in Clarivate Analytics products and services. Beginning with V. 7 (1) 2015.

AskBisht

Indexed in AskBisht.com

Facebook

FOLLOW US

MJHID in EuroPub Database

EuroPub

CLL UpDate

Keywords

Mediterranean Journal of Hematology and Infectious Diseases

is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. The MJHID is indexed and abstracted in Science Citation Index Expanded and Journal Citation Reports/InCites beginning with V. 7 (1) 2015.

eISSN: 2035-3006

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.